Intervention not reported
mirtazapine:citalopram · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
mirtazapine:fluoxetine · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
mirtazapine:paroxetine · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
mirtazapine:sertraline · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
mirtazapine:venlafaxine · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
mirtazapine:vilazodone · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with mirtazapine (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
Paroxetine probably leads to higher failure to respond at 1‐4 weeks compared with mirtazapine (moderate certainty).
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
Paroxetine showed no clear difference in failure to respond at 16‐24 weeks compared with mirtazapine (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · patients with depression
Paroxetine probably leads to higher failure to remit at endpoint compared with mirtazapine (moderate certainty).
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with mirtazapine (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with mirtazapine (moderate certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine probably leads to higher failure to respond (reduction ≥ 50% on HDRS) compared with mirtazapine (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with mirtazapine (moderate certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with mirtazapine (moderate certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with mirtazapine (moderate certainty).
1 finding from 1 review